Key clinical point: Preexisting osteoporosis is an important risk factor for death in postmenopausal women who develop multiple myeloma.
Major finding: Risk of death was elevated in women at high risk of fracture (covariate-adjusted hazard ratio, 1.51; 95% confidence interval, 1.01-2.25; P = .044) versus women with low fracture risk.
Study details: Retrospective analysis of the Women’s Health Initiative data set including 362 postmenopausal women who were cancer free at baseline and developed myeloma over the course of study follow-up.
Disclosures: The analysis was supported in part by the National Cancer Institute. The researchers reported having no relevant financial disclosures.
Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.
This Week's Must Reads
Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.
ctDNA may predict survival, treatment response in DLBCL, Kurtz DM et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.78.5246.
Post-discharge rivaroxaban does not change VTE risk, Spyropoulos AC et al. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1805090.
Restrictive transfusion strategy in CV surgery doesn't raise long-term risk, Mazer CD et al. N Engl J Med. 2018 Aug 26. doi:10.1056/NEJMoa1808561
Promise of SGN-CD70A against NHL eclipsed by adverse events, Phillips T et al. Invest New Drugs. 2018 Aug 22. doi: 10.1007/s10637-018-0655-0.